Drugs / MORAb-066
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01761240 | Jun 2013 → Feb 2016 | adenocarcinoma, breast cancer, colorectal cancer, malignant pancreatic neoplasm +1 | Morphotek | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MORAb-066 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01761240 ↗ |
| Modality | Monoclonal antibody | “an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb)” NCT01761240 ↗ |
| Route | Intravenous | “MORAb-066 is administered IV once weekly” NCT01761240 ↗ |